• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 24, 2021

TR1 – Lanstead – Major Holding in Shares

Read More
December 20, 2021

Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price

Read More
November 29, 2021

Collaboration with Imperial College London

Read More
November 18, 2021

CORPORATE UPDATE – The Evolution of ImmuPharma

Read More
October 01, 2021

EURONEXT DELISTING – Date: 18 October 2021

Read More
September 30, 2021

Prof. Sylviane Muller awarded prestigious Legion d’honneur.’

Read More
September 29, 2021

Corporate Update

Read More
September 29, 2021

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021

Read More
August 24, 2021

Director & PDMR Share Purchases

Read More
August 17, 2021

Lanstead Capital TR1

Read More
August 12, 2021

FDA approves the Lupzuor™ PK study

Read More
July 30, 2021

BOARD CHANGES

Read More
  • 1
  • 2
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved